MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) had no approved therapy until resmetirom in 2024. Resmetirom commercial uptake has been measured by hepatology referral patterns, fibrosis-stage diagnostic workup, and payer coverage; FGF21 analogues, GLP-1 plus glucagon dual agonists, and PPAR-pan agonists are reading out as follow-on options. The diagnostic-pathway question (FibroScan-based fibrosis assessment, MRI-PDFF, hepatology referral) is the gating commercial enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.